V1RA2 inhibitors represent a specialized class of chemical compounds designed to specifically interact with and inhibit the activity of the V1RA2 protein. These inhibitors are distinguished by their unique chemical structures, which are tailored to bind effectively to the V1RA2 protein. The core structure of V1RA2 inhibitors often includes a diverse array of organic molecules, featuring aromatic rings, heterocycles, and various functional groups. These components are strategically engineered to fit into the protein's binding site, engaging in a series of interactions such as hydrogen bonding, hydrophobic interactions, and van der Waals forces to ensure strong and specific binding.
The design and synthesis of V1RA2 inhibitors involve advanced organic synthesis techniques, including multi-step chemical reactions and the application of combinatorial chemistry. Researchers employ molecular modeling and high-throughput screening methods to identify and optimize compounds that demonstrate strong inhibitory activity against V1RA2. The synthetic process typically includes the careful construction of molecular frameworks to enhance binding affinity and specificity. By leveraging these sophisticated chemical techniques, V1RA2 inhibitors are developed to provide a detailed understanding of the molecular interactions between the inhibitors and the V1RA2 protein. This detailed structural insight is essential for studying the biochemical and molecular functions of V1RA2 in various research contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
A cell-permeable calcium chelator that can indirectly affect V1R45 by altering intracellular calcium levels, crucial for signal transduction. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
A tyrosine kinase inhibitor, which can indirectly impact V1R45 signaling by inhibiting downstream signaling pathways. | ||||||
KT 5720 | 108068-98-0 | sc-3538 sc-3538A sc-3538B | 50 µg 100 µg 500 µg | $138.00 $220.00 $972.00 | 47 | |
A PKA inhibitor that could modulate the signaling pathways involved in V1R45 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, potentially affecting the signaling pathways that V1R45 participates in. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor, which could indirectly influence V1R45 activity by affecting MAPK/ERK pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor, potentially altering the signaling pathways associated with V1R45. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
A calmodulin antagonist, which could indirectly affect V1R45 signaling by modulating calcium signaling pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor, which could affect cytoskeletal arrangements, indirectly influencing V1R45 signaling. | ||||||